2,055 active funding opportunities
Supports multidisciplinary research programs to develop new drugs and neurostimulation devices for mental and substance use disorders with academia-industry partnerships.
Supports research advancing discovery and development of new treatments and devices for mental and substance use disorders.
Supports renewal applications for existing NINDS clinical trial cooperative agreements needing more time and resources to complete trials.
Supports early-stage drug development for Alzheimer's disease including pre-clinical and Phase I clinical testing of novel therapies.
Supports development and dissemination of computational tools to analyze dynamic brain circuits and understand neural mechanisms across scales.
Funds research education to enhance knowledge of substance use disorders for clinicians and clinical researchers.
Supports established investigators to build research and educational infrastructure in aging and Alzheimer's Disease without leading independent clinical trials.
Supports NINDS intramural neurologist- and neurosurgeon-scientists transitioning to independent faculty roles with research and clinical activities.
Supports NINDS intramural neurologist- and neurosurgeon-scientists transitioning to independent academic faculty positions with research and clinical activities.
Supports advanced pre-clinical research to translate nanotechnology-based cancer diagnostics and therapeutics for improved treatment.
Supports innovative multisite clinical trials and observational studies leveraging NICHD network infrastructure for women, children, pregnant/lactating women, and persons with disabilities.
Supports research on novel newborn screening methods and therapies for fatal or disabling conditions and high priority genetic disorders.
Funds pilot projects to study understudied proteins linked to rare diseases, supporting preliminary data and tool development.
Funds research on novel newborn screening methods and therapies for fatal or disabling conditions, including high priority genetic disorders.
Funds basic mechanistic research on biological/genetic causes of cancer health disparities, including new methods and secondary data analyses.
Funds basic research on harmful effects of acute exposure to ultra-potent synthetic opioids like fentanyl and carfentanil, including delayed pathophysiological impacts.
Supports foundational basic and applied research proposals to advance Army science and technology capabilities.
Supports innovative analysis of existing data to study drug use behaviors, prevention, and health service utilization.
Supports innovative analysis of existing data to study drug use behaviors, prevention, and health service utilization, excluding clinical trials.
Supports early translational research to identify and characterize therapeutic candidates for HLBS diseases, facilitating product development and entrepreneurship.
Funds early-stage medical device prototype design, disease target identification, and assay development for HLBS diseases to advance translational research.
Funds early translational research to identify therapeutic candidates and prototypes for HLBS diseases, advancing projects toward human testing readiness without clinical trials.
Funds early translational support for prototype testing and assay development targeting HLBS diseases to advance products toward in vivo testing readiness.
Funds validation of transformative platforms to accelerate detection, diagnosis, and treatment of HLBS diseases.
